Compounds / Immune / LL-37

LL-37

LL-37 (Human Cathelicidin Antimicrobial Peptide)

ImmuneWell ResearchedFDA: Not approved

Overview

Chronic venous leg ulcers, diabetic foot ulcers, pressure ulcers. Anti-biofilm. Immune modulation.

Mechanism of Action

Only human cathelicidin. Broad-spectrum antimicrobial. Modulates innate immune response. Promotes wound healing and angiogenesis. Anti-biofilm activity.

Pharmacokinetics

Half-life

30 min

Peak (Tmax)

30 min

Cleared

~2.5 hrs

Molecular Profile

Molecular weight

4493.3 Da

CAS number

154947-66-7

Key Research Findings

Antimicrobial; wound healing; anti-biofilm; innate immune modulation.

Published Research

J Immunol (2013)

Kahlenberg JM, Kaplan MJ. Little peptide, big effects: LL-37 in inflammation

View source

Related Immune Compounds

Thymosin Alpha-1 Thymalin Thymulin VIP (Vasoactive Intestinal Peptide)

Clinical Guidance

Research data is not a treatment plan. If you are considering LL-37, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.

Running LL-37? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator · Full deep dive · Peptide fundamentals